Details

Titel

IGEN Leveraging Food Safety Tests to Detect Human Infectious Diseases

Ist Teil von

• PR Newswire, 2001, p.1

Ort / Verlag

New York: PR Newswire Association LLC

Erscheinungsjahr

2001

Link zum Volltext

Beschreibungen/Notizen

• This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the possible utility of PATHIGEN tests for human diagnostics, anticipated growth in the market for such tests, the company's plans to complete development of and regulatory requirements for PATHIGEN tests and the M-SERIES M1 analyzer for human diagnostic applications, and the planned launch dates of these products. Actual results might differ materially from these statements due to risks and uncertainties, including those associated with technical challenges, market conditions, market acceptance of new products, development of competitive products, and changes in government regulation. More complete descriptions of the risks applicable to IGEN appear in the company's documents filed with the Securities and Exchange Commission and available on request from the company. IGEN disclaims any intent or obligation to update these forward-looking statements. IGEN develops and markets biological detection systems based on its proprietary ORIGEN technology, which provides a unique combination of sensitivity, reliability, speed, and flexibility. ORIGEN-based systems are used in a wide variety of applications, including clinical diagnostics, pharmaceutical research and development, life science research, and industrial testing for food safety and quality control. These systems are marketed by IGEN and its licensees and/or distributors -- Roche Diagnostics, Organon Teknika, Eisai Co. Ltd., Sumitomo Corp., and Sanko Junyaku Co. Ltd. IGEN and ORIGEN are registered trademarks, and PATHIGEN and M-SERIES are trademarks, of IGEN International Inc. More information about the company can be found at http://www.igen.com .